Tourmaline Bio (TRML) Stock Forecast & Price Target

Compare

541 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TRML Analyst Ratings

Strong Buy

11 Buy

0 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Tourmaline

Bio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TRML Stock 12 Month Forecast

Average Price Target

$54.89

▲(220.81%Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Tourmaline Bio in the last 3 months. The average price target is $54.89 with a high forecast of $70.00 and a low forecast of $35.00. The average price target represents a 220.81% change from the last price of $17.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","71":"$71","26.75":"$26.8","41.5":"$41.5","56.25":"$56.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$54.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,26.75,41.5,56.25,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.85,21.861538461538462,25.873076923076923,29.884615384615387,33.89615384615385,37.90769230769231,41.91923076923077,45.93076923076923,49.94230769230769,53.95384615384616,57.965384615384615,61.97692307692308,65.98846153846154,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.85,20.69923076923077,23.548461538461538,26.39769230769231,29.24692307692308,32.09615384615385,34.94538461538462,37.79461538461538,40.643846153846155,43.49307692307693,46.34230769230769,49.191538461538464,52.040769230769236,{"y":54.89,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.85,19.169230769230772,20.48846153846154,21.80769230769231,23.126923076923077,24.446153846153848,25.76538461538462,27.084615384615386,28.403846153846153,29.723076923076924,31.042307692307695,32.36153846153846,33.68076923076923,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.59,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.54,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.71,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.34,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.23,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.66,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$70.00

Average Price Target$54.89

Lowest Price Target$35.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yi ChenH.C. Wainwright

H.C. Wainwright

$50

Buy

192.23%

Upside

Reiterated

05/27/25

Promising Phase 2 Trial Results and Strategic Advantages Justify Buy Rating for Tourmaline Bio

Thomas SmithLeerink Partners

Leerink Partners

$49→$54

Buy

215.60%

Upside

Reiterated

05/22/25

Tourmaline Bio (TRML) PT Raised to $54 at Leerink PartnersLeerink Partners analyst Thomas Smith raised the price target on Tourmaline Bio (NASDAQ: TRML) to $54.00 (from $49.00) while maintaining a Outperform rating.

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/21/25

Truist Financial Keeps Their Buy Rating on Tourmaline Bio (TRML)

Rami KatkhudaLifeSci Capital

LifeSci Capital

$58

Buy

238.98%

Upside

Reiterated

05/20/25

Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential

Kostas BiliourisBMO Capital

BMO Capital

$35

Buy

104.56%

Upside

Reiterated

05/20/25

Promising Potential of Tourmaline Bio's TOUR006: A Strong Buy Recommendation

Unknown AnalystGuggenheim

Not Ranked

Guggenheim

$55

Buy

221.45%

Upside

Reiterated

05/04/25

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Reiterated

04/23/25

Cantor Fitzgerald reiterates Overweight Rating on Tourmaline Bio (TRML)Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and {REMOVEPT} price target on Tourmaline Bio (NASDAQ: TRML).

Daniil GataulinChardan Capital

Chardan Capital

$70

Buy

309.12%

Upside

Initiated

04/22/25

Tourmaline Bio (TRML) Gets a Buy from Chardan Capital

Roger SongJefferies

Jefferies

$64

Buy

274.05%

Upside

Reiterated

04/21/25

Tourmaline Bio's Strategic Advancements and Financial Strength Drive Buy Rating

Laura ChicoWedbush

Wedbush

$42→$43

Buy

151.32%

Upside

Reiterated

03/14/25

Tourmaline Bio (TRML) Gets a Buy from Wedbush

Yasmeen RahimiPiper Sandler

Piper Sandler

$65

Buy

279.89%

Upside

Reiterated

03/10/25

Piper Sandler Sticks to Their Buy Rating for Tourmaline Bio (TRML)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yi ChenH.C. Wainwright

H.C. Wainwright

$50

Buy

192.23%

Upside

Reiterated

05/27/25

Promising Phase 2 Trial Results and Strategic Advantages Justify Buy Rating for Tourmaline Bio

Thomas SmithLeerink Partners

Leerink Partners

$49→$54

Buy

215.60%

Upside

Reiterated

05/22/25

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/21/25

Truist Financial Keeps Their Buy Rating on Tourmaline Bio (TRML)

Rami KatkhudaLifeSci Capital

LifeSci Capital

$58

Buy

238.98%

Upside

Reiterated

05/20/25

Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential

Kostas BiliourisBMO Capital

BMO Capital

$35

Buy

104.56%

Upside

Reiterated

05/20/25

Promising Potential of Tourmaline Bio's TOUR006: A Strong Buy Recommendation

Unknown AnalystGuggenheim

Not Ranked

Guggenheim

$55

Buy

221.45%

Upside

Reiterated

05/04/25

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Reiterated

04/23/25

Daniil GataulinChardan Capital

Chardan Capital

$70

Buy

309.12%

Upside

Initiated

04/22/25

Tourmaline Bio (TRML) Gets a Buy from Chardan Capital

Roger SongJefferies

Jefferies

$64

Buy

274.05%

Upside

Reiterated

04/21/25

Tourmaline Bio's Strategic Advancements and Financial Strength Drive Buy Rating

Laura ChicoWedbush

Wedbush

$42→$43

Buy

151.32%

Upside

Reiterated

03/14/25

Tourmaline Bio (TRML) Gets a Buy from Wedbush

Yasmeen RahimiPiper Sandler

Piper Sandler

$65

Buy

279.89%

Upside

Reiterated

03/10/25

Piper Sandler Sticks to Their Buy Rating for Tourmaline Bio (TRML)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tourmaline Bio

1 Month

xxx

Success Rate

4/7 ratings generated profit

Average Return

+20.93%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +20.93% per trade.

3 Months

xxx

Success Rate

4/7 ratings generated profit

Average Return

+27.24%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +27.24% per trade.

1 Year

Srikripa DevarakondaTruist Financial

Success Rate

7/11 ratings generated profit

Average Return

+7.08%

reiterated a buy rating 15 days ago

Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +7.08% per trade.

2 Years

xxx

Success Rate

7/11 ratings generated profit

Average Return

+9.63%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of +9.63% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TRML Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TRML has received 24 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TRML average Analyst price target in the past 3 months is 54.89.

Each month's total comprises the sum of three months' worth of ratings.

TRML Financial Forecast

TRML Earnings Forecast

Next quarter’s earnings estimate for TRML is -$0.93 with a range of -$1.05 to -$0.78. The previous quarter’s EPS was -$0.89. TRML beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year TRML has Outperformed its overall industry.

No data currently available

TRML Sales Forecast

Next quarter’s sales forecast for TRML is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TRML beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year TRML has Preformed in-line its overall industry.

TRML Stock Forecast FAQ

What is TRML’s average 12-month price target, according to analysts?

Based on analyst ratings, Tourmaline Bio’s 12-month average price target is 54.89.

What is TRML’s upside potential, based on the analysts’ average price target?

Tourmaline Bio has 220.81% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TRML a Buy, Sell or Hold?

Tourmaline Bio has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.

What is Tourmaline Bio’s price target?

The average price target for Tourmaline Bio is 54.89. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $70.00 ,the lowest forecast is $35.00. The average price target represents 220.81% Increase from the current price of $17.11.

What do analysts say about Tourmaline Bio?

Tourmaline Bio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of TRML?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Tourmaline Bio (TRML) Stock Forecast & Price Target

TRML Analyst Ratings

TRML Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Tourmaline Bio

TRML Analyst Recommendation Trends

TRML Financial Forecast

TRML Earnings Forecast

TRML Sales Forecast

TRML Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts